Article info
Extended reports
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
- Correspondence to:
Mr E N van Roon
Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, PO Box 888, 8901 BR Leeuwarden, Netherlands; e.n.van.roonznb.nl
Citation
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
Publication history
- Accepted August 12, 2004
- First published September 2, 2004.
Online issue publication
January 09, 2022
Article Versions
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Copyright information
Copyright 2005 by Annals of the Rheumatic Diseases